Dashboard
Manage Tickers

ACAD


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rbc-capital-maintains-outperform-on-acadia-pharmaceuticals-lowers-price-target-to-32
RBC Capital Maintains Outperform on ACADIA...
11/06/2025 15:35:13

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price tar...

beyond-the-numbers-6-analysts-discuss-acadia-pharmaceuticals-stock
Beyond The Numbers: 6 Analysts Discuss ACA...
11/06/2025 11:45:35

needham-maintains-buy-on-acadia-pharmaceuticals-raises-price-target-to-29
Needham Maintains Buy on ACADIA Pharmaceut...
11/06/2025 10:07:05

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $28 to ...

correction-acadia-pharmaceuticals-q3-adj-eps-026-beats-015-estimate-sales-278633m-beat-276466m-estimate
CORRECTION: ACADIA Pharmaceuticals Q3 Adj....
11/05/2025 22:54:03

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate o...

acadia-pharmaceuticals-raises-fy2025-sales-guidance-from-1045b-1095b-to-1070b-1095b-vs-1072b-est
ACADIA Pharmaceuticals Raises FY2025 Sales...
11/05/2025 21:44:37

Full Year 2025 Financial GuidanceTotal Revenues in the range of $1.070 to $1.095 billion, compared with the prior guidance rang...

acadia-pharmaceuticals-q3-eps-042-may-not-be-comparable-to-014-estimate-sales-278633m-beat-276466m-estimate
ACADIA Pharmaceuticals Q3 EPS $0.42 May No...
11/05/2025 21:43:08

earnings-scheduled-for-november-5-2025
Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

acadia-pharmaceuticalss-earnings-a-preview
ACADIA Pharmaceuticals's Earnings: A Preview
11/04/2025 18:01:37

this-acadia-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday
This ACADIA Pharmaceuticals Analyst Begins...
10/21/2025 12:35:30

citigroup-initiates-coverage-on-acadia-pharmaceuticals-with-buy-rating-announces-price-target-of-33
Citigroup Initiates Coverage On ACADIA Pha...
10/21/2025 10:51:16

Citigroup analyst Yigal Nochomovitz initiates coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy rating and announc...

acadia-pharmaceuticals-to-present-acp-711-and-acp-204-updates-nuplazid-analysis-at-2025-international-parkinsons-congress-october-5-9-2025
Acadia Pharmaceuticals To Present ACP-711 ...
10/02/2025 13:06:46

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced one late-breaker oral platform presentation and two poster presentati...

beyond-the-numbers-11-analysts-discuss-acadia-pharmaceuticals-stock
Beyond The Numbers: 11 Analysts Discuss AC...
09/29/2025 14:03:05

In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide a...

jp-morgan-maintains-overweight-on-acadia-pharmaceuticals-lowers-price-target-to-33
JP Morgan Maintains Overweight on ACADIA P...
09/29/2025 12:10:00

JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ: ACAD) with a Overweight and lowers the price target...

needham-maintains-buy-on-acadia-pharmaceuticals-lowers-price-target-to-28
Needham Maintains Buy on ACADIA Pharmaceut...
09/24/2025 14:54:06

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30 to ...

acadia-pharma-faces-trial-setback-as-prader-willi-syndrome-trial-falls-short
Acadia Pharma Faces Trial Setback As Prade...
09/24/2025 14:05:05

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/24/2025 12:10:28

trading-halt-halt-status-updated-at-72500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:25:...
09/24/2025 11:25:04

acadias-phase-3-compass-pws-trial-of-intranasal-carbetocin-fails-to-meet-primary-endpoint-in-prader-willi-hyperphagia
Acadia's Phase 3 COMPASS PWS Trial Of Intr...
09/24/2025 11:02:53

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the ef...

trading-halt-halted-at-65513-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:55:13 a.m. ET - ...
09/24/2025 10:55:17

acadia-pharma-announces-publication-of-interim-results-from-lotus-study-on-daybue-for-rett-syndrome-in-developmental-medicine-and-child-neurology-journal
Acadia Pharma Announces Publication Of Int...
09/12/2025 20:07:49

-- Findings reinforce efficacy and tolerability profile in patients prescribed DAYBUE in the U.S. for as long as 12 months, con...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION